Regencell Bioscience Holdings, an early-stage biotech focused on Traditional Chinese Medicine treatments for neurodevelopmental disorders, witnessed an unprecedented stock surge of over 64,000% in a single week in mid-2025. The rally was driven by speculative buying and a 38-for-1 stock split, which drastically increased share liquidity and retail investor interest. Despite zero revenue and unproven treatments, shares prices peaked at $83.60 before falling sharply. The stock experienced multiple trading halts amid extreme volatility. This speculative frenzy echoes previous meme-stock phenomena, underscoring risks in biotech investing dominated by hype rather than fundamental advances.